ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026

Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors.

Rujiao Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.